Last news
Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020

Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020

...

UL Solutions Joins Forces with SIRIM Berhad to Expand Fire Door Testing

UL Solutions Joins Forces with SIRIM Berhad to Expand Fire Door Testing

...

LOTTE BIOLOGICS to Kick off their CDMO Business Campaign at 'BIO International Convention 2023'

LOTTE BIOLOGICS to Kick off their CDMO Business Campaign at 'BIO International Convention 2023'

...

raicoon's unique solar performance guarantee accelerating the energy transition, backed by Munich Re Group

raicoon's unique solar performance guarantee accelerating the energy transition, backed by Munich Re Group

...

Innovent Presents Phase 1b Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2023 ASCO Annual Meeting

Innovent Presents Phase 1b Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2023 ASCO Annual Meeting

...

VVN539 met primary study endpoints in US phase IIa clinical study for the treatment of glaucoma

VVN539 met primary study endpoints in US phase IIa clinical study for the treatment of glaucoma

...

COMPUTEX closed on a High Note

COMPUTEX closed on a High Note

...

UTS ranked in the top 20 universities globally for the second year in a row by an international index on sustainable development

UTS ranked in the top 20 universities globally for the second year in a row by an international index on sustainable development

...

menu
menu